drugset
drugset / Trial / NCT01961960

A Study to Evaluate Intramuscular ASP7374

NCT01961960 ↗

Phase 3 Completed 55 enrolled UMN Pharma Inc.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374 in adults ≥61 years of age.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP7374 Vaccine — Intramuscular

Indications

influenza